Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Apr 17, 2017
Insider Transaction Report
Form 4
CHAMPSI FARAH
Director
Transactions
- Sale
Common Stock
2017-04-17$82.48/sh−43,001$3,546,722→ 148,143 total(indirect: See Footnote) - Sale
Common Stock
2017-04-17$83.06/sh−100$8,306→ 148,043 total(indirect: See Footnote) - Sale
Common Stock
2017-04-13$82.39/sh−72,275$5,954,737→ 191,144 total(indirect: See Footnote)
Holdings
- 79,152
Common Stock
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $82.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F2]Reflects the disposition by Alta Partners VIII, L.P. ("APVIII") of 1,500,000 shares of the Issuer's common stock in a pro-rata distribution to its limited partners on October 19, 2016. Also reflects the transfer from the reporting person to APVIII of 487 shares of the Issuer's common stock on January 26, 2017 and 975 shares of the Issuer's common stock on March 23, 2017. The reporting person has been awarded certain restricted stock units in her capacity as a director of the Company (the "RSUs"), and she is contractually obligated, as a managing director of APVIII, to transfer to APVIII, for no consideration, all shares of common stock that she receives upon the vesting of the RSUs.
- [F3]The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $83.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]Includes 58,998 shares received in a pro-rata distribution from APVIII. In prior reports, the reporting person reported beneficial ownership of all shares of the Issuer's common stock held by APVIII. Also reflects the transfer from the reporting person to APVIII of 487 shares of the Issuer's common stock on January 26, 2017 and 975 shares of the Issuer's common stock on March 23, 2017. The reporting person has been awarded certain RSUs in her capacity as a director of the Company, and she is contractually obligated, as a managing director of APVIII, to transfer to APVIII, for no consideration, all shares of common stock that she receives upon the vesting of the RSUs.